MARK OKAMOTO, PHARMD
Department of Pharmacy Practice
Dean and Chief Academic Officer 
Tenured Professor of Pharmacy


Mark Okamoto

Contact

Email: pharmdean@pcom.edu
Office: 678-407-7340
Research Page

Dr. Mark Okamoto is the Dean of the Department of Pharmacy. He also serves as Chief Academic Officer for Georgia Campus - Philadelphia College of Osteopathic Medicine.

 

  • Education

    • PharmD, University of Southern California
    • Residency, General Medicine, Los Angeles County / U.S.C. Medical Center
    • Fellowship, Infectious Disease (Pharmacokinetics), Los Angeles County / U.S.C. Medical Center
    • Fellowship, Advanced Infectious Disease (Pharmacoeconomics), Los Angeles County / U.S.C. Medical Center
  • Awards

    • Rho Chi National Pharmaceutical Honor Society / University of Southern California. Limited to top 20% of the class
    • Dean’s List Scholar, 1986, 1987, 1988. Requires minimum GPA of 3.5 for consideration
    • Faculty Service Award / University of Southern California. Presented for meritorious service to the School
    • Clerkship of the Year / University of California, San Francisco. Presented for teaching excellence
    • Most Outstanding Faculty Member / Western University of Health Sciences, College of Pharmacy
    • Marquis Who’s Who in America
    • Who’s Who Among American Teachers
    • Teacher of the Year / Western University of Health Sciences
    • Teacher of the Year / PCOM School of Pharmacy
    • Peach Teaching Award
  • Publications

    Selected Publications

    • Okamoto MP, Chin A, Gill MA. A comparison of two Bayesian pharmacokinetic programs in the prediction of serum gentamicin concentrations. Clinical Pharmacy (1990); 9:708-711.
    • Okamoto MP, Chin A, Gill MA, Sclar DA, Berne TV, Yellin AE, Heseltine PN, Appleman MD. Analysis of cefepime tissue penetration into human appendix. Pharmacotherapy (1991); 11:353-58.
    • Okamoto MP, Gill MA, Nakahiro RK, Bedikian A, Chin A, Yellin AE, Berne TV, Knupp CA. Cefepime pharmacokinetics in patients undergoing elective cholecystectomy. Clinical Pharmacv, (1993); 12:134-137.
    • Okamoto MP Nakahiro RK, Chin A, Bedikian A. Cefepime clincal pharmacokinetics. Clinical Pharmacokinetics (1993); 25(2): 88-102.
    • Okamoto MP, Ho, S. Evaluating the clinical literature. In: Millares M, ed. Applied Drug Information: Strategies for Information Management. Vancouver, WA: Applied Therapeutics, 1998: 6.1-6.49.
    • Bounthavong M, Okamoto MP. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. J Eval Clin Pract 2007; 13(3):453-460.
    • Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy 2001; 21(11):1337-1344.

    Selected Presentations

    • Okamoto MP. Tissue penetration of cefepime into human appendix. ACCP 11th annual meeting, San Francisco, CA (August, 1990)
    • Okamoto MP. Cefepime pharmacokinetics in plasma, peritoneal fluid, bile fluid, and gallbladder wall tissue. ACCP 12th Annual Meeting, Minneapolis, Minnesota (August, 1991).
    • Okamoto MP. Introduction to Pharmacoeconomics. Inland Society of Health-System Pharmacists. Riverside, CA. Continuing Education course (June 1999).
    • Okamoto MP. Pharmacoeconomics of cefmetazole versus cefoxitin in patients with penetrating abdominal trauma. Pfizer research forum (New York NY, April 1993).
  • Grants

    1989 (PI). Tissue penetration of cefepime into human appendix. Bristol-Myers Squibb:

    1990 (PI): Penetration of cefepime into gallbladder tissue in patients undergoing cholecystectomy. Bristol-Myers Squibb

    1990 (PI). A cost benefit analysis of cefepime versus gentamicin/clindamycin in acute cholecystitis. Bristol -Myers Squibb:

    1991 (Co-I). Cost-effectiveness of transdermal delivery systems for antihypertensive medication. Boehringer Ingelheim Pharmaceuticals, Inc.

    1991 (Co-I). Determination of fluconazole in human serum by solid phase extraction and reversed phase HPLC. Glaxo Pharmaceuticals

    1992 (PI). Pharmacoeconomic evaluation of a pharmacist managed hypertension clinic. The Upjohn Company

    1994 (PI). The use of Alpha Adrenergic Blockers in the Treatment of Benign Prostatic Hypertrophy. Kaiser Permanente Regional Research Grant.

    1997 (PI). Socioeconomic evaluation of fluoxetine, paroxetine and sertraline in a managed care setting. Eli Lilly and Company:

    2003 (Co-PI). Evaluation of outcomes of community based disease state management programs: Asthma & Diabetes. Community Pharmacy Foundation

    2009 (Co-I). Multi-scale analysis and knowledge structuring for natural products. National Science Foundation – Science and technology centers

  • Other

    Editorial Board

    Annals of Pharmacotherapy (2003-present)
    Chair – Medication Therapy Management section (2011-present)
    Current Medicinal Chemistry – Anti Infective Agents (2000-present)

    Peer Reviewer

    International Society for Pharmacoeconomic & Outcomes Research (ISPOR) Pharmacoeconomics
    Expert Review of Pharmacoeconomics & Outcomes Research
    Annals of Pharmacotherapy
    Pharmacotherapy
    Journal of Pharmacy Technology
    Clinical Pharmacy American Journal of Health-System Pharmacy
    Clinical Therapeutics
    Drugs
    Clinical Drug Investigation
    Clinical Pharmacokinetics
    American Journal of Respiratory Medicine
    Journal of Managed Care Pharmacy
    Journal of Clinical Anesthesia